Globus Medical (GMED) Stock Forecast, Price & News

Globus Medical (NYSE:GMED) Frequently Asked Questions

Is Globus Medical a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Globus Medical stock.
View analyst ratings for Globus Medical or view top-rated stocks.

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,400,000 shares, an increase of 30.6% from the April 30th total of 3,370,000 shares. Based on an average daily trading volume, of 843,100 shares, the days-to-cover ratio is presently 5.2 days.
View Globus Medical's Short Interest.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Globus Medical.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings data on Tuesday, May, 10th. The medical device company reported $0.42 earnings per share for the quarter, missing analysts' consensus estimates of $0.47 by $0.05. The medical device company earned $230.55 million during the quarter, compared to analyst estimates of $232.88 million. Globus Medical had a trailing twelve-month return on equity of 11.95% and a net margin of 14.77%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.49 EPS.
View Globus Medical's earnings history.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided earnings per share (EPS) guidance of $2.10-$2.10 for the period, compared to the consensus EPS estimate of $2.10. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.03 billion.

What price target have analysts set for GMED?

10 brokerages have issued 12 month target prices for Globus Medical's shares. Their forecasts range from $70.00 to $100.00. On average, they anticipate Globus Medical's stock price to reach $83.91 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price.
View analysts' price targets for Globus Medical or view top-rated stocks among Wall Street analysts.

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:

• Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 55, Pay $965.08k)
• Mr. David M. Demski, CEO, Pres & Director (Age 64, Pay $1.48M) (LinkedIn Profile)
• Mr. Keith W. Pfeil, Sr. VP & CFO (Age 43, Pay $619.87k) (LinkedIn Profile)
• Ms. Kelly G. Huller Esq., Sr. VP & Gen. Counsel (Age 49, Pay $504.26k)
• Mr. Daniel T. Scavilla, Exec. VP, Chief Commercial Officer & Pres of Trauma (Age 57, Pay $864.45k) (LinkedIn Profile)
• Mr. Brian J. Kearns, Sr. VP of Bus. Devel. & Investor Relations (Age 55)
• Mr. A. Brett Murphy, Exec. VP of International Sales (Age 57)
• Mr. Steven M. Payne, VP & Controller (Age 51)
• Mr. Mike Reeder, Exec. Officer
• Mr. Richard Holifield, Exec. Officer

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical CEO David Demski on Glassdoor.com. David Demski has an approval rating of 61% among Globus Medical's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Globus Medical's key competitors?

Some companies that are related to Globus Medical include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of GMED's competitors.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.29%), BlackRock Inc. (7.24%), Wellington Management Group LLP (3.19%), State Street Corp (2.19%), RTW Investments LP (1.66%) and Champlain Investment Partners LLC (1.65%). Company insiders that own Globus Medical stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends for Globus Medical.

Which institutional investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., abrdn plc, Arrowstreet Capital Limited Partnership, Vanguard Group Inc., First Trust Advisors LP, Van Berkom & Associates Inc., Champlain Investment Partners LLC, and Vident Investment Advisory LLC. Company insiders that have sold Globus Medical company stock in the last year include Daniel T Scavilla, David D Davidar, James R Tobin, Keith W Pfeil, and Kelly Huller.
View insider buying and selling activity for Globus Medical or view top insider-selling stocks.

Which institutional investors are buying Globus Medical stock?

GMED stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Dimensional Fund Advisors LP, Boston Trust Walden Corp, Fuller & Thaler Asset Management Inc., CQS US LLC, Global Alpha Capital Management Ltd., State Street Corp, and Natixis Advisors L.P..
View insider buying and selling activity for Globus Medical or or view top insider-buying stocks.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $66.82.

How much money does Globus Medical make?

Globus Medical has a market capitalization of $6.79 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.36 on an earnings per share basis.

How many employees does Globus Medical have?

Globus Medical employs 2,400 workers across the globe.

What is Globus Medical's official website?

The official website for Globus Medical is www.globusmedical.com.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at (610) 930-1800, via email at [email protected], or via fax at 610-930-2042.